Recombinant human thrombopoietin biosimilar(Biolotus Biotech Ltda.)

Tegra Medical announces new director of sales and marketing in Europe Tegra Medical announced that it appointed Darren Vine as its director of sales and marketing in Europe. Franklin, Mass.-based Tegra said in a news release that Vine will report to CEO and head of SFS division medical Walter Kobler, with responsibilities including the building of the company’s presence through expansion into new markets around the… […] 5 challenges Boston Scientific overcame to make single-use scopes work FDA wanted single-use scopes to reduce potentially deadly superbug infections. Here’s how Boston Scientific made it happen. Boston Scientific’s Exalt Model D Single-Use Duodenoscope received FDA clearance in December 2019. It was the first device of its kind to hit the medical market. Just five months earlier, the FDA urged device manufacturers to move away from re-usable duodenoscopes with… […] Veranex acquires Experien Group Veranex announced today that it acquired Experien Group, a provider of regulatory, quality and clinical consulting services for medtech companies. Raleigh, N.C.-based Veranex, which was created as a combination of companies after Summit Partners acquired Ximedica, Quartesian and Boston Healthcare Associates in June, offers integrated product development strategies and services to medtech companies. According to… […] How Olympus is using AI to find patients for its COPD device Olympus recently announced its SeleCT Connect program, which uses diagnostic imaging AI to automatically screen which people might benefit from its Spiration valve system. Spiration is an FDA-designated breakthrough device for treating chronic obstructive pulmonary disease (COPD) patients. SeleCT Connect — offered as part of Olympus’ SeleCT quantitative computer tomography (QCT) analysis service — is… […] Catheter & Medical Design and VitalDyne Medical rebrand as VitalPath Catheter & Medical Design and VitalDyne Medical — makers of complex medical catheter systems — have rebranded under the name VitalPath. The move comes about five months after CMD’s March 2021 acquisition of VitalDyne. The Roseville, Minn.–based company also has a new website at vitalpath.com. VitalPath will exhibit at booth No. 1714 at MD&M West,… […] Dymax touts newest formulations for medtech wearables Dymax is using MD&M West in Anaheim, Calif. next week to tout its newest formulations for assembling medical device wearables. The Dymax materials are free from IBOA and TPO, are compatible with common and difficult substrates, and have passed ISO 10993-10 for sensitization and irritation, according to the Torrington, Conn.–based company. For manufacturers involved with… […] What is a proportional isolation valve? A “proportional” isolation valve can bring the next level of control and design for engineers, especially in life science industries. Doug Paynter, Clippard When we talk about proportional valves, whether they are pneumatic or hydraulic, we typically refer to valves that vary their flow path when you apply an increasing or decreasing amount of power/current… […] CoorsTek scores EU legal win in pink components trademark dispute The EU Trademark Court of Appeals in Paris recently upheld a Paris EU Trademark High Court decision that sided with CoorsTek against CeramTec in a trademark dispute over “pink” ceramic hip components. The Paris Court of Appeals in its June 2021 ruling upheld the cancelations of the three EU trademarks and the dismissal of CeramTec’s… […] Abbott CMO Dr. Nick West touts latest iteration of drug-eluting stent Abbott executive Dr. Nick West believes the company offers the “best-in-class” drug-eluting stent with its Xience platform. When Abbott (NYSE:ABT) CMO & divisional VP of global medical affairs Dr. Nick West looks back at his use of drug-eluting stents in the early 2000s, all he sees now is innovation. As a practicing interventional cardiologist, West remembers… […] Versapor® RC Membranes: The next generation of venting materials As the world leader in the design and production of membranes, filtration devices, and separation systems, Pall Corporation supplies products to nearly every industry in the world. Founded in 1946, Pall Corporation has set the standard for filtration solutions for 75 years and counting. Our customers have relied on us for their most sophisticated applications… […]

Dublin, Dec. 30, 2020 (GLOBE NEWSWIRE) -- The "Doptelet (Avatrombopag) - Drug Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. Doptelet (avatrombopag) - Drug Insight and Market Forecast - 2030 report by the publisher outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Doptelet (avatrombopag) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.Doptelet (avatrombopag) is a second generation, once daily, orally administered TPO receptor agonist approved for the treatment of thrombocytopenia in adult patients with CLD who are scheduled to undergo a procedure. Doptelet is designed to mimic the effects of TPO, the primary regulator of normal platelet production. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists. In the ADAPT-1 and ADAPT-2 clinical trials, there was 1 treatment-emergent event of portal vein thrombosis in a patient (n=1/430) with chronic liver disease and thrombocytopenia treated with Doptelet. The drug should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts. In April 2020, AkaRx announced Doptelet has been granted approval from the China National Medical Products Administration (NMPA) for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure (i.e., the CLD indication).Scope of the report Doptelet (avatrombopag) Analytical PerspectiveIn-depth Doptelet (avatrombopag) Market AssessmentThis report provides a detailed market assessment of Doptelet (avatrombopag) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.Doptelet (avatrombopag) Clinical AssessmentThe report provides the clinical trials information of Doptelet (avatrombopag) covering trial interventions, trial conditions, trial status, start and completion dates.Report highlights Key Questions Answered For more information about this report visit Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.